IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

ISSN
0975-2366
5 - Years Impact Factor

Year 2012 - 2016

Impact Factor: 1.55

Total Publications: 317

Total Citation: 491

Year 2011 - 2015

Impact Factor: 1.46

Total Publications: 326

Total Citation: 477

Year 2010 - 2014

Impact Factor: 1.3

Total Publications: 313

Total Citation: 407

Year 2009 - 2013

Impact Factor: 0.973

Total Publications: 293

Total Citation: 285

Current Issue
22nd NATIONAL CONVENTION

22nd National Convention of Society of Pharmacognosy & International Conference. For more details visit


For More Detail Visit ncsp.ganpatuniversity.ac.in
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPRT ISSUE

January - March 6 [1] 2014

Click to download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
PIPPHARMACON & IJPR 2018

PIPPHARMACON & IJPR 2018

Click to download
 

Article Detail

Label
Label
Evaluating Cardiac Safety of Trastuzumab in Iraqi Women with Breast Cancer

Author: BAHIR RAZZAQ, SABA RABEE ABDUL AZIZ, FATIMA THABET MOHSEN
Abstract: Trastuzumab,an immunotherapy which indicated for overexpression of human epidermal growth factor receptor 2 (HER2) in breast cancer disorders, with a risk of cardiac toxicity. This study was design to present the incidence of cardiac toxicity and its associated risk factors for breast cancer women receiving trastuzumab.This retrospective observational study enrolled 50 women with positive HER2 breast cancer who received trastuzumab in theBaghdad Oncology Centers, from August 2017 to March 2018. The incidence of cardiotoxicity and associated risk factors during treatment withtrastuzumab was evaluated. From 50 patient,18 (36%) exhibited cardiac complications, 12 % of them reduced their LVEF below 50%, 30% reduced their LVEF >10 points below their baseline, while 6% reduced their LVEF >15 points below their baseline.Of those 18, 8 patients (44.4%) stopping treatment because of drop in LVEF. In 7 of those patients, trastuzumab re-administered after normalization of EF values.Treatment course of trastuzumab was completed in 98% (49 patients), while2% (1 patient) required trastuzumab discontinuation definitively, as LVEF not recovered completely. Risk factors for cardiac toxicity included: patients elder than 65 years (p < 0.046), patients with low baseline LVEF (p < 0.027), those with concomitant and previous radiotherapy to the left side of the chest (p < 0.039), and those with elevated troponin levels at baseline (p < 0.034). In this study, trastuzumab-related cardiotoxicitywas comparable with that of literature data.This toxicityrepresented by asymptomatic LVEFreduction and less frequently symptomaticcardiac dysfunction. Most cases were transient and reversible.
Keyword: breast cancer; trastuzumab;cardiotoxicity;risk factors.
DOI: https://doi.org/10.31838/ijpr/2019.11.01.065
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
AICTE INTERNATIONAL CONFERENCE

AICTE Sponsored International Conference on Challenges, Opportunities and Newer Directions of Pharmacovigilance and Clinical Research in India

Download Brochure


For More Detail Visit www.pippharmacon.org
News & Events
Google Scholar

hit counters free
0.07
2017CiteScore
 
11th percentile
Powered by  Scopus
Impact Factor for five years is 1.55 (2012 - 2016)

Year 2011 - 2015 Impact Factor - 1.46 Total Publications - 326 Total Citations - 477